InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Goldberg Mark Alan, Director. Director active across 3 companies, notably Glycomimetics INC. In total, 17 reports have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €270k. History available since 18 May 2021. The latest transaction was disclosed on 12 June 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations17 total
2,242 shares0Common StockSEC:0001415889-24-016981:0
4,584 shares@ US$3.0033.4% of flowCommon StockSEC:0001415889-24-009744:0
60,720 sharesCommon StockSEC:0001104659-24-014708:0
569 shares@ US$29.657.6% of flowCommon StockSEC:0001415889-24-000376:0
5,827 shares@ US$2.3632.5% of flowCommon stockSEC:0001209191-24-000067:0
10,000 shares@ US$14.7069.1% of flowCommon StockSEC:0001415889-23-014675:0
9,167 shares@ US$1.5034.1% of flowCommon stockSEC:0001209191-23-051449:0
1,063 shares@ US$15.877.9% of flowCommon StockSEC:0001415889-23-013757:0
894 shares@ US$18.877.7% of flowCommon StockSEC:0001415889-23-010821:0
2,600 shares0Common StockSEC:0001415889-23-010263:0
4,394 shares@ US$3.847.7% of flowCommon StockSEC:0001415889-23-006057:0
2,600 shares0Common StockSEC:0001415889-22-007131:0
5,000 shares@ US$59.98100.0% of flowCommon StockSEC:0001415889-22-002653:0
Ideal exit: 28 Nov 2022 (T+270)
2,250 shares0Common StockSEC:0001179110-21-006420:0
2,250 shares0Common StockSEC:0001179110-21-006420
5,250 shares0Common StockSEC:0001209191-21-036378:0
5,250 shares0Common StockSEC:0001209191-21-036378
17 of 17 declarations
About Goldberg Mark Alan
Mark Alan Goldberg is a Board Member at GlycoMimetics Inc. and Blueprint Medicines Corp. He contributes to the governance of both companies, bringing his expertise in the biopharmaceutical sector. His role is essential in guiding GlycoMimetics and Blueprint in their growth and innovation strategies.
